J. Van-ark-otte, M. Kedde, . Van-der, and W. Vijgh, Determinants of CPT-11 and SN-38 activities in human lung cancer cells, British Journal of Cancer, vol.77, issue.12, pp.2171-2176, 1998.
DOI : 10.1038/bjc.1998.362

K. Tan, M. Mattern, W. Eng, F. Mccabe, and R. Johnson, Nonproductive Rearrangement of DNA Topoisomerase I and II Genes: Correlation With Resistance to Topoisomerase Inhibitors, JNCI Journal of the National Cancer Institute, vol.81, issue.22, pp.1732-1735, 1989.
DOI : 10.1093/jnci/81.22.1732

A. Saleem, T. Edwards, Z. Rasheed, and E. Rubin, Mechanisms of Resistance to Camptothecins, Annals of the New York Academy of Sciences, vol.1, issue.1, pp.46-55, 2000.
DOI : 10.1111/j.1749-6632.2000.tb07024.x

Y. Sugimoto, S. Tsukahara, T. Oh-hara, T. Isoe, and T. Tsuruo, Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody, Cancer Res, vol.50, pp.6925-6930, 1990.

I. Husain, J. Mohler, H. Seigler, and J. Besterman, Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy, Cancer Res, vol.54, pp.539-546, 1994.

S. Park, W. Lam, and Y. Cheng, X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance, Cancer Res, vol.62, pp.459-465, 2002.

Y. Pommier, C. Redon, and V. Rao, Repair of and checkpoint response to topoisomerase I-mediated DNA damage, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol.532, issue.1-2, pp.173-203, 2003.
DOI : 10.1016/j.mrfmmm.2003.08.016

C. Gongora, L. Candeil, and N. Vezzio, Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38, Cancer Biology & Therapy, vol.7, issue.6, pp.822-832, 2008.
DOI : 10.4161/cbt.7.6.5838

T. Zarubin and J. Han, Activation and signaling of the p38 MAP kinase pathway, Cell Research, vol.62, issue.1, pp.11-18, 2005.
DOI : 10.1038/ng894

A. Cuenda and S. Rousseau, p38 MAP-Kinases pathway regulation, function and role in human diseases, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol.1773, issue.8, pp.1358-1375, 2007.
DOI : 10.1016/j.bbamcr.2007.03.010

K. Wilson, M. Fitzgibbon, and P. Caron, Crystal Structure of p38 Mitogen-activated Protein Kinase, Journal of Biological Chemistry, vol.271, issue.44, pp.27696-27700, 1996.
DOI : 10.1074/jbc.271.44.27696

J. Ventura, S. Tenbaum, and E. Perdiguero, p38?? MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation, Nature Genetics, vol.92, issue.6, pp.750-758, 2007.
DOI : 10.1006/meth.2001.1262

V. Robinson, J. Hickson, V. Griend, D. Dubauskas, Z. Rinker-schaeffer et al., MKK4 and metastasis suppression: a marriage of signal transduction and metastasis research, Clinical and Experimental Metastasis, vol.20, issue.1, pp.25-30, 2003.
DOI : 10.1023/A:1022586318678

E. Wagner and A. Nebreda, Signal integration by JNK and p38 MAPK pathways in cancer development, Nature Reviews Cancer, vol.136, issue.8, pp.537-549, 2009.
DOI : 10.1038/nrc2694

F. Chiacchiera and C. Simone, Signal-dependent regulation of gene expression as a target for cancer treatment: Inhibiting p38?? in colorectal tumors, Cancer Letters, vol.265, issue.1, pp.16-26, 2008.
DOI : 10.1016/j.canlet.2008.02.061

N. Vi-É, V. Copois, and C. Bascoul-mollevi, Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells, Molecular Cancer, vol.7, issue.1, p.14, 2008.
DOI : 10.1186/1476-4598-7-14

M. Avitzour, R. Diskin, B. Raboy, N. Askari, D. Engelberg et al., Intrinsically active variants of all human p38 isoforms, FEBS Journal, vol.461, issue.4, pp.963-975, 2007.
DOI : 10.1111/j.1742-4658.2007.05644.x

D. Subramanian, E. Kraut, A. Staubus, D. Young, and M. Muller, Analysis of topoisomerase I/DNA complexes in patients administered topotecan, Cancer Res, vol.55, pp.2097-2103, 1995.

V. Granci, F. Bibeau, and A. Kramar, Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas, European Journal of Cancer, vol.44, issue.15, pp.2312-2318, 2008.
DOI : 10.1016/j.ejca.2008.06.042
URL : https://hal.archives-ouvertes.fr/inserm-00318854

D. Rio, M. Molina, F. Bascoul-mollevi, and C. , Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan, J Clin Oncol, vol.25, pp.773-780, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00147002

C. Wood, T. Thornton, G. Sabio, R. Davis, and M. Rincon, Nuclear Localization of p38 MAPK in Response to DNA Damage, International Journal of Biological Sciences, vol.5, pp.428-437, 2009.
DOI : 10.7150/ijbs.5.428

R. Woessner, W. Eng, and G. Hofmann, Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content, Oncol Res, vol.4, pp.481-488, 1992.

X. Wang, K. Diener, and C. Manthey, Molecular Cloning and Characterization of a Novel p38 Mitogen-activated Protein Kinase, Journal of Biological Chemistry, vol.272, issue.38, pp.23668-23674, 1997.
DOI : 10.1074/jbc.272.38.23668

Y. Arakawa, H. Suzuki, S. Saito, and H. Yamada, Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells, Molecular Cancer Therapeutics, vol.5, issue.3, pp.502-508, 2006.
DOI : 10.1158/1535-7163.MCT-05-0246

M. Van-der-merwe and M. Bjornsti, Alters DNA Topoisomerase I Active Site Architecture and Sensitivity to Camptothecin, Journal of Biological Chemistry, vol.283, issue.6, pp.3305-3315, 2008.
DOI : 10.1074/jbc.M705781200

C. Losasso, E. Cretaio, P. Fiorani, D. Annessa-'i, G. Chillemi et al., A single mutation in the 729 residue modulates human DNA topoisomerase IB DNA binding and drug resistance, Nucleic Acids Research, vol.36, issue.17, pp.5635-5644, 2008.
DOI : 10.1093/nar/gkn557

F. Chiacchiera, A. Matrone, and E. Ferrari, p38?? blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1??- to FoxO-dependent transcription, Cell Death and Differentiation, vol.4, issue.9, pp.1203-1214, 2009.
DOI : 10.2174/092986705774462914

S. Adachi, M. Shimizu, and Y. Shirakami, (-)-Epigallocatechin gallate downregulates EGF receptor via phosphorylation at Ser1046/1047 by p38 MAPK in colon cancer cells, Carcinogenesis, vol.30, issue.9, pp.1544-52, 2009.
DOI : 10.1093/carcin/bgp166

S. Winograd-katz and A. Levitzki, Cisplatin induces PKB/Akt activation and p38MAPK phosphorylation of the EGF receptor, Oncogene, vol.272, issue.56, pp.7381-90, 2006.
DOI : 10.1038/sj.onc.1209737

H. Reinhardt, A. Aslanian, J. Lees, and M. Yaffe, p53-Deficient Cells Rely on ATM- and ATR-Mediated Checkpoint Signaling through the p38MAPK/MK2 Pathway for Survival after DNA Damage, Cancer Cell, vol.11, issue.2, pp.175-89, 2007.
DOI : 10.1016/j.ccr.2006.11.024

F. Comes, A. Matrone, and P. Lastella, A novel cell type-specific role of p38?? in the control of autophagy and cell death in colorectal cancer cells, Cell Death and Differentiation, vol.5, issue.4, pp.693-702, 2007.
DOI : 10.1124/jpet.106.106054

H. Zhao, A. Ooyama, and M. Yamamoto, Molecular Basis for the Induction of an Angiogenesis Inhibitor, Thrombospondin-1, by 5-Fluorouracil, Cancer Research, vol.68, issue.17, pp.7035-7041, 2008.
DOI : 10.1158/0008-5472.CAN-07-6496

S. Chiu, J. Chao, Y. Lee, and T. Hsu, Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells, Toxicology Letters, vol.179, issue.2, pp.63-70, 2008.
DOI : 10.1016/j.toxlet.2008.04.004

X. Ling, X. He, P. Apontes, F. Cao, R. Azrak et al., Enhancing effectiveness of the MDR-sensitive compound T138067 using advanced treatment with negative modulators of the drug-resistant protein surviving, Am J Transl Res, vol.1, pp.393-405, 2009.

M. Gutierrez, S. Detre, and S. Johnston, Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein Kinase, Journal of Clinical Oncology, vol.23, issue.11, pp.2469-2476, 2005.
DOI : 10.1200/JCO.2005.01.172

D. Owens and S. Keyse, Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases, Oncogene, vol.176, issue.22, pp.3203-3213, 2007.
DOI : 10.1074/jbc.274.50.35526

J. Wen, Y. Feng, and W. Huang, Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition, Leukemia Research, vol.34, issue.1
DOI : 10.1016/j.leukres.2009.05.024